Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Program Scaling topic
No spam. Unsubscribe anytime.
VA official cites lung-precision (LPOP) and CCRN as models to expand precision oncology to 100+ sites
Summary
A VA official told a committee that the lung precision-oncology program (LPOP) and the Cancer Clinical and Research Network (CCRN) were used as models to expand precision oncology, increasing molecular testing rates and expanding site participation from an initial ~21 prostate sites to more than 100.
A VA official described how the department used an existing lung precision-oncology rollout and the Cancer Clinical and Research Network (CCRN) to expand precision oncology capacity across VA medical centers.
The official said the lung program, LPOP, ran at roughly 114 sites and helped raise molecular testing rates for lung cancer to "over 80 percent," and that experience informed VA’s approach to the prostate program. The official said initial prostate program sites were identified by the Prostate Cancer Foundation (14 sites) and that VA and partners added seven more, reaching 21, and then expanded the initiative through the CCRN “to over a 100 sites.”
The VA official also said LPOP enabled a large screening footprint, saying it rolled out "basically from nothing, to, over 1000000 lung cancer screens," and called that scale a successful model to emulate for other cancers. The official emphasized that molecular testing rates for prostate cancer were still lagging compared with lung cancer and that using centralized testing services and networked sites were central components of VA’s strategy.
The committee member acknowledged the explanation and the exchange concluded without a formal vote or directive recorded in the transcript.
